0001193125-21-240310.txt : 20210908 0001193125-21-240310.hdr.sgml : 20210908 20210809145158 ACCESSION NUMBER: 0001193125-21-240310 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Eliem Therapeutics, Inc. CENTRAL INDEX KEY: 0001768446 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832273741 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 23515 NE NOVELTY HILL ROAD STREET 2: SUITE B221 #125 CITY: REDMOND STATE: WA ZIP: 98053 BUSINESS PHONE: 425-276-2300 MAIL ADDRESS: STREET 1: 23515 NE NOVELTY HILL ROAD STREET 2: SUITE B221 #125 CITY: REDMOND STATE: WA ZIP: 98053 CORRESP 1 filename1.htm CORRESP

August 9, 2021

Via EDGAR Submission

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:

Sasha Parikh

Vanessa Robertson

Dillon Hagius

Jeffrey Gabor

 

  Re:

Eliem Therapeutics, Inc.

Registration Statement on Form S-1, as amended

File No. 333-257980

Dear Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as the representatives of the several underwriters, hereby join in the request of Eliem Therapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement, as amended, so that it becomes effective at 4:00 p.m. Eastern Time on August 9, 2021, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Act, we, as the representatives of the several underwriters, wish to advise you that between August 2, 2021 through the date hereof we have distributed approximately 1,050 copies of the Company’s Preliminary Prospectus dated August 2, 2021 to prospective underwriters, dealers, institutional investors and others.

We, the undersigned, as the representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

(signature page follows)

Very truly yours,
SVB LEERINK LLC
EVERCORE GROUP L.L.C.
STIFEL, NICOLAUS & COMPANY, INCORPORATED
GUGGENHEIM SECURITIES LLC
Acting severally on behalf of themselves and the several underwriters
SVB LEERINK LLC
By:   /s/ Murphy Gallagher
Name:   Murphy Gallagher
Title:   Senior Managing Director
EVERCORE GROUP L.L.C.
By:   /s/ Edward Baxter
Name:   Edward Baxter
Title:   Senior Managing Director
STIFEL, NICOLAUS & COMPANY, INCORPORATED
By:   /s/ Nathan Thompson
Name:   Nathan Thompson
Title:   Director
GUGGENHEIM SECURITIES LLC
By:   /s/ Jordan Bliss
Name:   Jordan Bliss
Title:   Senior Managing Director

 

(Signature Page to Acceleration Request Letter)